Eli Lilly and Boehringer drug gets head start at FDA

Jardiance has been awarded "priority review" status by the US Food and Drug Administration in a new indication.
by marketwire, translated by catherine brett

Eli Lilly and its partner Boehringer Ingelheim have been granted special status at the FDA for their drug Jardiance, to speed up its journey to market as a preventive therapy for heart failure in patients who are not suffering from reduced ventricle functioning.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading